Page last updated: 2024-12-04

chloroacetaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID33
CHEMBL ID506976
CHEBI ID27871
MeSH IDM0045789

Synonyms (56)

Synonym
chloroaldehyde
inchi=1/c2h3clo/c3-1-2-4/h2h,1h
acetaldehyde, chloro-
einecs 203-472-8
2-chloro-1-ethanal
ccris 856
rcra waste number p023
alpha-chloroacetaldehyde
rcra waste no. p023
un2232
2-chloroacetaldehyde
brn 1071226
chloroethanal
hsdb 2521
monochloroacetaldehyde
chloroacetaldehyde monomer
107-20-0
C06754
chloroacetaldehyde ,
2-chloroethanal
chloroacetaldehyde (caa)
CHEBI:27871 ,
CHEMBL506976
AKOS000118948
NCGC00248308-01
ec 203-472-8
unii-cf069f5d9c
2-chloroethanal [un2232] [poison]
acetaldehyde, 2-chloro-
4-01-00-03134 (beilstein handbook reference)
cf069f5d9c ,
NCGC00255050-01
cas-107-20-0
dtxcid60292
tox21_301152
dtxsid4020292 ,
BP-13328
STL264246
chloroacetaldehyde [hsdb]
chloroacetaldehyde [mi]
chloracetaldehyde
chloro acetaldehyde
chloroactaldehyde
clch2cho
chloro-acetaldehyde
chloroacetoaldehyde
ch2clcho
un 2232
chloroacetalaldehyde
mfcd00006992
J-509000
2-chloro-acetaldehyde
Q1950418
STR01221
EN300-19136
chloroacetaldehyde (~45per cent in water)

Research Excerpts

Overview

Chloroacetaldehyde (CAA) is a metabolite of the human carcinogen vinyl chloride. It is putatively responsible for renal damage following anti-tumor therapy with IFO.

ExcerptReferenceRelevance
"Chloroacetaldehyde (CAA) is a metabolite of the human carcinogen vinyl chloride. "( DNA damage and mutations produced by chloroacetaldehyde in a CpG-methylated target gene.
Choi, JH; Pfeifer, GP, 2004
)
2.04
"Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO. "( Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
Benesic, A; Freudinger, R; Gekle, M; Groezinger, F; Kirchhoff, A; Mildenberger, S; Schwerdt, G; Wollny, B, 2006
)
3.22
"Chloroacetaldehyde (CA) is a nephrotoxic and neurotoxic metabolite of the anticancer drug ifosfamide (IFA) and is a dose-limiting factor in IFA-based chemotherapy. "( High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations.
Huang, Z; Waxman, DJ, 1999
)
1.98

Effects

ExcerptReferenceRelevance
"Chloroacetaldehyde has been shown to be a urinary metabolite of cyclophosphamide in the rat. "( 2-Chloroacetaldehyde: a metabolite of cyclophosphamide in the rat.
Graham, MI; McLean, AE; Shaw, IC, 1983
)
2.43

Toxicity

Cyclophosphamide and ifosfamide are two commonly used DNA-alkylating agents in cancer chemotherapy. They undergo biotransformation to several toxic and non-toxic metabolites. The toxic metabolite of IFO thought to be responsible for IFO-induced kidney damage is chloroacetaldehyde (CAA)

ExcerptReferenceRelevance
" 4-OH-IF and 4-OH-CP were significantly more toxic than the parent drugs."( Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.
Ansorge, S; Brandis, M; Mohrmann, M; Schmich, U; Schönfeld, B, 1994
)
0.29
", this toxic effect is not accompanied by an increase in intramyocardial citrate levels."( A 13C NMR study of 2-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism.
Loqueviel, C; Malet-Martino, M; Martino, R, 1997
)
0.59
"Renal injury is a common side effect of the chemotherapeutic agent ifosfamide."( Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells.
Chan, K; Davies, S; Lu, H; Springate, J; Taub, M, 1999
)
0.57
" We have developed transgenic cell lines to examine the potential for either human ALDH1A1 or ALDH3A1 to protect against damage mediated by these toxic aldehydes."( Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells.
Bunting, KD; Haynes, RL; Leone-Kabler, S; Szweda, L; Townsend, AJ; Wu, Y, 2001
)
0.31
" The sensitivity of pediatric tubules to the toxic effects of CAA and the rate of their CAA uptake were not statistically different from those found in adult tubules."( Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules.
Baverel, G; Cochat, P; Dubourg, L; Michoudet, C; Tanière, P, 2002
)
0.69
"Renal injury is a common side effect of the chemotherapeutic agent ifosfamide."( Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
Springate, JE; Taub, M; Zaki, EL, 2003
)
0.32
" With cyclophosphamide it shares a toxicity profile characterized by myelosuppression and urotoxicity, but ifosfamide has additionally disclosed adverse neurological effects."( Neurological toxicity of ifosfamide.
Giometto, B; Nicolao, P, 2003
)
0.32
"Renal injury is a common side effect of the chemotherapeutic agent ifosfamide."( Ifosfamide toxicity in cultured proximal renal tubule cells.
Springate, J; Taub, M, 2007
)
0.34
" coli genome from the toxic effects of CAA."( AlkB influences the chloroacetaldehyde-induced mutation spectra and toxicity in the pSP189 supF shuttle vector.
Dedon, PC; Delaney, JC; Essigmann, JM; Kim, MY; Taghizadeh, K; Wogan, GN; Zhou, X, 2007
)
0.66
" The toxic metabolite of IFO thought to be responsible for IFO-induced kidney damage is chloroacetaldehyde (CAA)."( Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention.
Chen, N; Hanly, L; Koren, G; Rieder, M, 2009
)
0.58
"1 to 180 mg/kg and reduced the production of a potential toxic metabolite chloroacetaldehyde (CAA) in animal plasma."( Protective effects of fomepizole on 2-chloroethanol toxicity.
Chen, YT; Hung, DZ; Liao, JW, 2010
)
0.59
"Since all the latter test compounds, like many toxic compounds, negatively interact with cellular metabolic pathways, we also illustrate our biochemical toxicology approach in which we used not only enzymatic but also carbon 13 NMR measurements and mathematical modelling of metabolic pathways."( Use of precision-cut renal cortical slices in nephrotoxicity studies.
Baverel, G; Duplany, A; El Hage, M; Ferrier, B; Gauthier, C; Knouzy, B; Martin, G, 2013
)
0.39
"Cyclophosphamide and ifosfamide are two commonly used DNA-alkylating agents in cancer chemotherapy that undergo biotransformation to several toxic and non-toxic metabolites, including acrolein and chloroacetaldehyde (CAA)."( Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.
Lau, V; MacAllister, SL; Martin-Brisac, N; O'Brien, PJ; Yang, K, 2013
)
0.95
" The analysis revealed toxic effects only for the treatment with 35 μmol·liter(-1) for 3 and 14 days."( Nephron Toxicity Profiling via Untargeted Metabolome Analysis Employing a High Performance Liquid Chromatography-Mass Spectrometry-based Experimental and Computational Pipeline.
Dekant, W; Hewitt, P; Huber, CG; Jennings, P; Kohlbacher, O; Limonciel, A; Ranninger, C; Reischl, R; Rurik, M; Ruzek, S; Wilmes, A, 2015
)
0.42
" Those results are in agreement with literature data reporting that intracellular CAA toxic concentrations range from 35 to 320 μM, after therapeutic ifosfamide dosing."( Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
Bois, FY; Hamon, J; Leclerc, E, 2016
)
0.72
"The equimolar produced metabolite DCCTX was chosen to reflect chloroacetaldehyde (CAA, a toxic metabolite of CTX) production in rats."( Schisandra chinensis extract decreases chloroacetaldehyde production in rats and attenuates cyclophosphamide toxicity in liver, kidney and brain.
Chen, L; Chen, W; Feng, G; Gao, S; Yin, J; Zhai, J; Zhang, F, 2018
)
0.99

Pharmacokinetics

ExcerptReferenceRelevance
" Independent of the route of ifosfamide application on day 1, the terminal half-life on day 3 (when the drug was given by the alternative route) was decreased in 6 out of the 12 patients, thus indicating self-induction of hepatic metabolism."( Metabolism and pharmacokinetics of oral and intravenous ifosfamide.
Cerny, T; Küpfer, A; Kurowski, V; Wagner, T, 1991
)
0.28
" As compared with the values obtained on day 1, on day 5 the terminal half-life and AUC values determined for IF were reduced by 30% (6."( Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Kurowski, V; Wagner, T, 1993
)
0.52
" Using pharmacokinetic modeling of experimental data, we show that the median level of chloroacetaldehyde in RT cells is 80 micromol/L, ranging from 35 to 320 micromol/L."( Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels.
Aleksa, K; Ito, S; Koren, G, 2004
)
0.79
" The peak concentration and area under the curve (AUC) were determined for the parent compound and the metabolites 4-hydroxyifosfamide and chloracetaldehyde in eight patients who received two cycles of ICE chemotherapy (ifosfamide 5 g/m(2) day 1, carboplatin 300 mg/m(2) day 1, etoposide 100 mg/m(2) days 1-3)."( Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Brüggemann, SK; Peters, SO; Pfäffle, S; Wagner, T, 2007
)
0.34
" A pharmacokinetic (PK) model described the production of CAA by the hepatocytes and its transport to the renal cells."( Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
Bois, FY; Hamon, J; Leclerc, E, 2016
)
0.72

Dosage Studied

ExcerptRelevanceReference
"3 mmol/l) displaces the dose-response curve for acrolein to the left, indicating an increased toxicity of the combination of acrolein plus Dimesna."( Ifosfamide and mesna: effects on the Na/H exchanger activity in renal epithelial cells in culture (LLC-PK1).
Brandis, M; Küpper, N; Mohrmann, M; Schönfield, B,
)
0.13
"0% VC in air produced similar mutant frequencies without a clear dose-response relationship, suggesting saturation of metabolic activation."( Mutagenicity of vinyl chloride and its reactive metabolites, chloroethylene oxide and chloroacetaldehyde, in a metabolically competent human B-lymphoblastoid line.
Chiang, SY; Skopek, TR; Swenberg, JA; Weisman, WH, 1997
)
0.52
" Similar dose-response curves were found for both metabolites."( Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide.
Brüggemann, SK; Kisro, J; Wagner, T, 1997
)
0.54
" The kinetics of the excretion were compared following short-term and continuous ifosfamide infusion at a dosage of 3 g/m2."( Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Blaschke, G; Boos, J; Hohenlöchter, B; Jürgens, H; Rossi, R; Silies, H, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Cyclophosphamide Action Pathway922
Ifosfamide Action Pathway821
Cyclophosphamide Metabolism Pathway922
Ifosfamide Metabolism Pathway821
Cyclophosphamide Pathway, Pharmacokinetics73
1,2-dichloroethane degradation115

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.94100.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency24.54120.001024.504861.6448AID743215
aryl hydrocarbon receptorHomo sapiens (human)Potency76.95880.000723.06741,258.9301AID743085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1337095Inhibition of human MPO2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1135701Mutagenicity in repair-deficient Bacillus subtilis assessed as growth inhibition at 0.1 M1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Mercaptoimidazolylpropionic acid hydrobromide. Inhibition of tadpole collagenase and related properties.
AID384212Mutagenic activity in Salmonella Typhimurium TA100 assessed as logarithm of his+ revertant number increasing activity by amens test2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (202)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (24.75)18.7374
1990's68 (33.66)18.2507
2000's51 (25.25)29.6817
2010's30 (14.85)24.3611
2020's3 (1.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.42 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index70.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.40%)5.53%
Reviews8 (3.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other203 (94.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]